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COMMENTS 
 
 Although a longer follow-up is needed, is probable that even children completely stabilized can probably not be kept on lower doses even though  
    the reduction of frequency of the infusions represent a lower social burden.                                                                    
INTRODUCTION 
 
 Gaucher disease (GD) is the most prevalent lysosomal storage disorder (1:50.000) 
 It is caused by an autosomal recessive inherited deficiency of the lysosomal enzyme  
  glucocerebrosidase.  
 Children and adolescents with GD are usually treated with  enzyme replacement therapy  
   (ERT) at an initial dose of 30-60U/kg body weight every 2 weeks. 
 In August 2009, due to an acute shortage in the supply of imiglucerase, a reduced dose  
   or a reduced infusion frequency was recommended. 
 
AIM 
 To evaluate the effects of a reduced infusion frequency of imiglucerase over 18 months  of follow-up 
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 POPULATION AND METHODS 
 
Patients with type 1 GD treated with ERT: 3 (1M:2F) 
Median actual age: 11 Y (range 7 - 21) 
Median age at symptoms onset:  6 Y (range 3 - 8)  
Median age at the beginning of treatment: 7y (range 5 - 12).  
Median duration of treatment before dose reduction: 3y (range 1 - 8).  
total regression of symptoms and hepatosplenomegaly  
normalization of hematological parameters 
 improvement of quitotriosidase 
In August 2009:  40-45U/Kg every 2 W  40-45U/Kg every 4 W 
Clinical and laboratory data were analyzed  
Hemoglobin, platelet count and chitotriosidase levels were analyzed 
  by linear regression 
Patient 1 Patient 2 Patient 3 
Gender F F M 
Date of birth 30/10/88 28/4/99 01/04/2003 
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Genetic study N370S/ g.3389-
3390delCT  
N370S/L444P N370S/p.D24N 
Beginning ERT February 2001 April 2006 May 2008 
 RESULTS  
 All patients remained asymptomatic 
 All patients remained with no major change on hematological parameters except for the patient with bone crisis who presented subnormal platelet count. 
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